Needham & Company LLC Reaffirms Buy Rating for Esperion Therapeutics (NASDAQ:ESPR)

Needham & Company LLC reiterated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a research report sent to investors on Monday, Benzinga reports. The brokerage currently has a $8.00 price target on the biopharmaceutical company’s stock.

Several other equities research analysts have also recently weighed in on ESPR. HC Wainwright cut their target price on Esperion Therapeutics from $22.00 to $16.00 and set a buy rating for the company in a research note on Wednesday, February 28th. Bank of America cut Esperion Therapeutics from a buy rating to a neutral rating in a research note on Wednesday, January 3rd. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, Esperion Therapeutics presently has an average rating of Hold and an average target price of $9.33.

Esperion Therapeutics Trading Down 3.0 %

Esperion Therapeutics stock opened at $2.62 on Monday. Esperion Therapeutics has a 12 month low of $0.70 and a 12 month high of $3.34. The stock’s 50 day moving average is $2.37 and its 200-day moving average is $1.80. The company has a market capitalization of $484.83 million, a price-to-earnings ratio of -1.24 and a beta of 0.82.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.03. The company had revenue of $32.25 million during the quarter, compared to the consensus estimate of $26.84 million. During the same quarter last year, the firm posted ($0.76) earnings per share. As a group, equities research analysts predict that Esperion Therapeutics will post -0.61 earnings per share for the current fiscal year.

Institutional Trading of Esperion Therapeutics

Large investors have recently bought and sold shares of the business. FMR LLC grew its holdings in Esperion Therapeutics by 30.0% during the 2nd quarter. FMR LLC now owns 8,669 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 2,003 shares during the period. Private Portfolio Partners LLC acquired a new stake in Esperion Therapeutics during the 4th quarter worth about $30,000. Principal Financial Group Inc. acquired a new stake in Esperion Therapeutics during the 1st quarter worth about $49,000. Amalgamated Bank grew its holdings in Esperion Therapeutics by 18.6% during the 4th quarter. Amalgamated Bank now owns 12,490 shares of the biopharmaceutical company’s stock worth $78,000 after acquiring an additional 1,960 shares during the period. Finally, Invesco Ltd. acquired a new stake in Esperion Therapeutics during the 1st quarter worth about $65,000. 47.39% of the stock is currently owned by institutional investors and hedge funds.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.